BIO President & CEO John F. Crowley writes Congress to urge PPRV passage; plus a deep dive into the impact of autoimmune disease on women. (761 words, 3 minutes, 48 seconds) “It is critical to pass ...

BIO Business Solutions ® is the largest cost savings purchasing program for the biotech industry operated by the Biotechnology Innovation Organization (BIO). With more than half a billion in annual ...

A busy week in Washington, D.C., brought legislation to fix the Inflation Reduction Act “pill penalty,” bipartisan calls for PBM reform, and BIO CEO John F. Crowley explaining why Congress needs to ...

Jubilant Therapeutics is a patient-focused biopharmaceutical company advancing potent and selective small molecule modulators to address specific unmet medical needs in oncology and autoimmune ...

WASHINGTON D.C. (February 25, 2025) – John Crowley, president and CEO of the Biotechnology Innovation Organization (BIO), released the following statement after Representatives Gregory Murphy (R-NC), ...

We’re getting ready for Rare Disease Day (February 28) with a look at how policy can support patients and how BIO is engaging with the FDA. (960 words, 4 minutes, 48 seconds) Ahead of Rare Disease Day ...

A collaborative initiative to advance corporate board diversity through partnerships and more.

BIO is committed to providing access to talent, access to capital, and building trust with consumers and patients. BIO Board Initiative A collaborative initiative to advance corporate board diversity ...

Measuring Diversity in the Biotech Industry: Advancing Equity and Inclusion BIO Board Initiative A collaborative initiative to advance corporate board diversity through partnerships and more.